Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer

The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encourag...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 30; číslo 14; s. 1594
Hlavní autoři:	Cortés, Javier, Fumoleau, Pierre, Bianchi, Giulia Valeria, Petrella, Teresa M, Gelmon, Karen, Pivot, Xavier, Verma, Shailendra, Albanell, Joan, Conte, Pierfranco, Lluch, Ana, Salvagni, Stefania, Servent, Veronique, Gianni, Luca, Scaltriti, Maurizio, Ross, Graham A, Dixon, Joanna, Szado, Tania, Baselga, José
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.05.2012
Témata:	Adult Age Factors Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Disease Progression Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Maximum Tolerated Dose Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Patient Selection Prognosis Prospective Studies Receptor, ErbB-2 - metabolism Risk Assessment Survival Analysis Trastuzumab Treatment Outcome
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!